Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Class III β-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial

21 Jun 2011

Abstract excerpt

PURPOSE: Platinum-based doublets are the cornerstone of treatment in advanced non-small-cell lung cancer (NSCLC) and often include vinorelbine or taxanes. A predictive biomarker is greatly needed to select chemotherapy-sensitive patients for these microtubule-interfering agents. Class III β-tubulin (TUBB3) has been shown of value in NSCLC, but evidence is not uniform. Accordingly, we explored the predictive role...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21690572
DOI: 10.1158/1078-0432.ccr-11-0658

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Class III β-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized TrialPMID 21690572Read ↗

High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.Semantic proximity Read ↗

Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients.Semantic proximity Read ↗

<i>TUBB3</i> /βIII-Tubulin Acts through the PTEN/AKT Signaling Axis to Promote Tumorigenesis and Anoikis Resistance in Non–Small Cell Lung CancerSemantic proximity Read ↗

Comprehensive Pancancer Analysis of TUBB6 as a Marker for Prognosis and Immunotherapy ResponseSemantic proximity Read ↗

[Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].Semantic proximity Read ↗

TUBB, a robust biomarker with satisfying abilities in diagnosis, prognosis, and immune regulation via a comprehensive pan-cancer analysisSemantic proximity Read ↗

Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal CancerSemantic proximity Read ↗

Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung CancerSemantic proximity Read ↗

mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

Bioinformatics Identification of TUBB as Potential Prognostic Biomarker for Worse Prognosis in ERα-Positive and Better Prognosis in ERα-Negative Breast CancerSemantic proximity Read ↗

Differential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC)Semantic proximity Read ↗

Prognostic biomarkers for HNSCC using quantitative real‐time PCR and microarray analysis: β‐tubulin isotypes and the p53 interactomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.